Earnings Call Summary | Enhabit(EHAB.US) Q4 2023 Earnings Conference
Earnings Call Summary | Enhabit(EHAB.US) Q4 2023 Earnings Conference
The following is a summary of the Enhabit, Inc. (EHAB) Q4 2023 Earnings Call Transcript:
以下是Enhabit, Inc.（EHAB）2023年第四季度業績電話會議記錄摘要：
Financial Performance:
財務業績：
Enhabit Inc. reported consolidated net revenue of $260.6 million for Q4, indicating a 1% decline YoY.
Adjusted EBITDA amounted to $25.2 million, marking a 16.8% decrease compared to the previous year.
Home health segment saw a growth of 3.9% in total admissions year-over-year.
In the hospice segment, revenue increased by 7.8% YoY, with its adjusted EBITDA increasing by $6.1 million.
Cost management efforts resulted in flat YoY cost per visit in the home health segment, and a minor increase in cost per visit in the hospice segment.
The company ended the year with a leverage ratio of 5.4x and available liquidity of $61 million, having generated approximately $59 million in free cash flow.
2024 guidance anticipates net service revenue between $1,076 billion to $1.102 billion and adjusted EBITDA of $98 million to $110 million.
Enhabit Inc.報告稱，第四季度合併淨收入爲2.606億美元，同比下降1％。
調整後的息稅折舊攤銷前利潤爲2520萬美元，與去年同期相比下降了16.8％。
家庭健康板塊的總入院人數同比增長3.9％。
在臨終關懷領域，收入同比增長7.8％，調整後的息稅折舊攤銷前利潤增加了610萬美元。
成本管理工作使家庭健康領域的每次就診費用同比持平，臨終關懷領域的每次就診費用略有增加。
該公司在年底的槓桿率爲5.4倍，可用流動性爲6,100萬美元，創造了約5900萬美元的自由現金流。
2024年的指引預計淨服務收入在10.76億美元至11.02億美元之間，調整後的息稅折舊攤銷前利潤爲9,800萬美元至1.1億美元。
Business Progress:
業務進展：
Enhabit has been focusing on its value proposition for payers, shifting Medicare Advantage volumes into payer innovation agreements, and managed to control costs effectively.
Despite a slight drop in admissions, the hospice operations indicate potential growth, with a sequential increase of 1.3% over the third quarter in the average daily census.
Enhabit has managed to strategically increase its non-episodic visits in new payer innovation contracts markedly from 5% in Q1 to 25% in Q4.
Investments in IT infrastructure and talent acquisition have led to an increase in home office general and administrative expenses.
The company's strategic plans for 2024 include stabilizing traditional Medicare as a percentage of total home health revenue, progressing in its payer innovation strategy, and increasing utilization of clinical resources.
The company secured a new national advanced episodic model contract, bolstering access to home care for patients being discharged from institutional settings.
The company plans the opening of 10 new locations in 2024, along with the completion of regulatory approval for two locations awaited from 2023.
Enhabit一直專注於其對付款人的價值主張，將Medicare Advantage的交易量轉移到付款人創新協議中，並設法有效地控制了成本。
儘管入院人數略有下降，但臨終關懷的業務仍顯示出潛在的增長，平均每日人口普查比第三季度連續增長1.3％。
Enhabit設法從戰略上將其新付款人創新合同的非偶發訪問量從第一季度的5％顯著增加到第四季度的25％。
對IT基礎設施和人才招聘的投資導致家庭辦公一般和管理費用增加。
該公司2024年的戰略計劃包括穩定傳統醫療保險佔家庭健康總收入的百分比，推進其付款人創新戰略，以及提高臨床資源的利用率。
該公司獲得了一份新的全國先進劇集模式合同，增加了從機構環境中出院的患者獲得家庭護理的機會。
該公司計劃在2024年開設10個新地點，並完成等待2023年開始的兩個地點的監管批准。
More details: Enhabit IR
更多詳情： Enhabit IR
Tips: For more comprehensive details, please refer to the IR website. The article is only for investors' reference without any guidance or recommendation suggestions.
提示：欲了解更多詳情，請訪問投資者關係網站。本文僅供投資者參考，不構成任何投資建議。
譯文內容由第三人軟體翻譯。